Ricevi le ultime notizie sulle azioni Acrivon Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ACRV

Ultime notizie per

ACRIVON THERAPEUTICS INC

Acrivon Therapeutics

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics Inc

Earnings

Press Releases

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer

News

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Management

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Health Care

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ACRV

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Celularity

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Cue Biopharma

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Evaxion

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

ImmuCell

MiNK Therapeutics

IO Biotech

Lite Strategy

Medicus Pharma

MediciNova

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OS Therapies

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Plus Therapeutics

Serina Therapeutics

Senti Biosciences

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

Comments

Acrivon Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO